Revolving Door

MEPs Marietje Schaake and Christian Engstrom submit question on appointment of Maria Martin-Prat to EU copyright post

70879-christian-engstrom-parti-pirate-suedois_250x350.jpg marietje-1.jpg On April 1, 2011, Marietje SCHAAKE and Christian ENGSTRÖM submitted a parliamentary question on the appointment of Maria Martin-Part as the new head of unit for copy

US Industry IP memo for the TPP negotiations leaked

Knowledge Ecology International (KEI) has received a copy of U.S. industry demands on the Intellectual Property chapter of the Trans-Pacific Partnership Agreement (TPP) negotiations. A draft letter from US industry to USTR has been leaked and is available here.

Revolving Door

Sergio Marchi

Ambassador Marchi was the Chair of the WTO General Council during the negotiation on Doha Paragraph 6.

Howard Dean as a shill for BIO, on Biosimilars bill

The July 20, 2009 issue of BioCentury has an extensive report on the “Biosimilar fire Drill.” It discusses in detail the lobbying by the Biotechnology Industry Association (BIO, to defeat efforts by President Obama, OMB, the FTC, Representative Waxman, Senator Brown, AARP, Public Citizen, PIRG, Consumers Union, KEI, Essential Action, and others, to reform the regulation to biologic medicines, so there is more generic competition.

Jon Santamauro, former US trade official now on BIO IGWG delegation

During the IGWG, BIO, the trade association, a group not yet in official relations with the WHO, was given the right to place four persons inside the closed drafting sessions. One of them was Jon Santamauro, who until recently was a US trade official on intellectual property issues.

“Mr. Santamauro has more than 15 years of experience handling intellectual property issues for the U.S. Government.”

Former WIPO employee (now with PhRMA) moonlights as BIO bouncer

Richard Kjeldgaard, a former Senior Counsellor in the Biotechnology and Genetic Resources Division of the World Intellectual Property Organization (WIPO) and now employed by the U.S. based Pharmaceutical Research and Manufacturers of America (PhRMA) performed his role as “bouncer” admirably today at a luncheon organized by the Biotechnology Industry Organization.

Syndicate content